Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Authors:
- 26 February 2025
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 111, 60-75
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Anhui Province (202308085MH271)
This publication has 191 references indexed in Scilit:
- Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular CarcinomaJAMA Oncology, 2024
- Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular CarcinomaJAMA Oncology, 2023
- Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With CancerJAMA Oncology, 2021
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology, 2020
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With CancerJAMA Oncology, 2020
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With NivolumabJAMA Oncology, 2019
- Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular CarcinomaJAMA Surgery, 2019
- Association of Immunotherapy With Overall Survival in Elderly Patients With MelanomaJAMA Dermatology, 2018
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National LevelJAMA Oncology, 2017
- The Effect of Age on the Long-term Prognosis of Patients With Hepatocellular Carcinoma After Resection SurgeryArchives of Surgery, 2012